GLP-1 Studio

Lilly registers two EloraTZP obesity trials, results years away
Both obesity studies are not yet recruiting, with completion dates set for November 2029.
CagriSema analysis: 25% weight loss in women at 68 weeks
CNBC: Novo said CagriSema was associated with 25% average weight loss in women in an analysis after a late-stage trial, versus 3% with placebo. Launch…
Medicaid GLP-1 spending swung by state in Q1 2026
California's Medicaid prescriptions for Wegovy, Zepbound and Saxenda dropped by more than three quarters in Q1 2026, while its total GLP-1 prescriptions…
Retatrutide trial: 21.9% weight loss in higher-BMI group
TRIUMPH-2 phase III trial data on retatrutide, an experimental triple receptor agonist, for obesity and type 2 diabetes, as reported by dailykos.com.
Man sues Novo Nordisk, says Ozempic left him legally blind
Ladbible reports the Engel family is suing Novo Nordisk, alleging the company did not warn patients and doctors about potential health risks connected…
A digital-first GLP-1 program reports six months of real-world data
The cohort had no comparator group and paid out of pocket, so the results show feasibility, not proof it works better.
EMA posts update on a new oral GLP-1 medicine
The agency describes a once-daily tablet as an alternative to other oral and injectable GLP-1 medicines.
Stolen insulin pens may be sold online as weight loss medication
nltimes.nl reports Novo Nordisk warned that thousands of stolen insulin pens may be sold online as weight loss medication, and that using insulin…
Counterfeit weight loss pens worth 2 million pounds seized in UK
A UK cohort study looked at tirzepatide treatment patterns around a price increase, and a separate cohort study found GLP-1 use associated with lower…
Lilly stock jumps 3.6% to crack IBD's Big Cap 20
Investor's Business Daily reports Eli Lilly shares rose 3.6% Thursday, joining its Big Cap 20 list of top-performing stocks.
Ireland weighs paying for more GLP-1 medications
The HSE is considering reimbursing more GLP-1s after receiving a number of applications, the Irish Times reports.
GLP-1 therapy tied to less psychiatric acute care in diabetes
An observational cohort study looked at adults with schizophrenia and type 2 diabetes, comparing GLP-1 therapy with DPP-4 and SGLT2 inhibitors.
© 2026 GLP-1 Studio LLC · Publisher Privacy ∙ Publisher Terms
Substack · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture